I asked ChatGPT for the best UK shares to buy now — its top pick surprised me…

Business woman creating images with artificial intelligence inside office

When I asked ChatGPT what the best UK shares to buy right now are, Rolls-Royce, BP, and Greggs all got honourable mentions. But its top pick was FTSE 100 firm AstraZeneca (LSE:AZN).

That surprised me a bit – the stock has slightly outperformed the FTSE 100 this year, but it’s still a lot cheaper than it was a year ago. Nonetheless, I have to admit the chatbot made a pretty good case.

AstraZeneca

AstraZeneca’s recent half-year results were pretty impressive. Revenues were up 18%, driven by strong sales of its own drugs and its collaborative projects with other organisations.

That’s impressive, but the real key is the outlook. According to ChatGPT, the company has a robust pipeline with around 40 projects in Phase III trials. 

The stock is also popular with analysts – the average price target is around 36% above the current share price. If it reaches that level in the next year, it might well be the best UK stock to own.

Despite this, I’m not looking to buy shares in AstraZeneca at the moment. I’ve nothing against what ChatGPT says about the stock, but I find it very hard to understand the company in detail

The pipeline is a good example. The average approval rate for Phase III drugs is around 60% but that doesn’t tell me much about the company specifically.

Given this, buying the stock would be a speculative – and therefore risky – move for me. So while ChatGPT might be on to something, AstraZeneca isn’t top of my list of UK shares to buy right now.

A different idea

WH Smith (LSE:SMWH) didn’t even feature on ChatGPT’s list of top stocks. But I don’t think it takes a lot of specialist knowledge to see why this is an investment that could work out well over time.

The company isn’t doing anything massively innovative in terms of cancer treatments or obesity medication. But it has just made a big move that I think is both significant and easy to understand.

Officially, WH Smith has just sold off its high street shops. In my view, it practically gave them away, but I don’t mind that since it means the firm can focus on its much more promising travel division.

These are stores located in airports, hospitals, and train stations. In other words, venues where there’s much less competition than there is on the high street.

That’s not to say there are no risks. A global recession is probably the biggest threat to the stock market overall and depending on travel demand makes WH Smith more exposed than most. 

Nonetheless, the stock has an enterprise value of £1.79bn and the travel stores generate around £189m in trading profits. On that basis, I think the stock is well worth considering. 

Investing principles

Will WH Smith do better than AstraZeneca in the future? I don’t know – a lot depends on what happens with the pharmaceutical company’s ongoing trials. 

If things go well, the stock could be an outstanding investment. But I’m not in a position to see this for myself, so I’m not buying the stock. 

More importantly, I don’t see a need to rely on ChatGPT for stock ideas. I think there are plenty of UK shares that look attractive at the moment that I can make sense of, so I’m focusing on those.

The post I asked ChatGPT for the best UK shares to buy now — its top pick surprised me… appeared first on The Motley Fool UK.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

More reading

Stephen Wright has positions in WH Smith. The Motley Fool UK has recommended AstraZeneca Plc, Greggs Plc, Rolls-Royce Plc, and WH Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.